Aggregation and metal-binding properties of mutant forms of the amyloid A beta peptide of Alzheimer's disease - PubMed (original) (raw)

Aggregation and metal-binding properties of mutant forms of the amyloid A beta peptide of Alzheimer's disease

A Clements et al. J Neurochem. 1996 Feb.

Abstract

The fibrillogenic properties of Alzheimer's A beta peptides corresponding to residues 1-40 of the normal human sequence and to two mutant forms containing the replacement Ala21 to Gly or Glu22 to Gln were compared. At pH 7.4 and 37 degrees C the Gln22 peptide was found to aggregate and precipitate from solution faster than the normal A beta, whereas the Gly21 peptide aggregated much more slowly. Electron microscopy showed that the aggregates all had fibrillar structures. Circular dichroism spectra of these peptides revealed that aggregation of the normal and Gln22 sequences was associated with spectral changes consistent with a transformation from random coil to beta sheet, whereas the spectrum of the Gly21 peptide remained almost unchanged during a period in which little or no aggregation occurred. When immobilised by spotting onto nitrocellulose membranes the peptides bound similar amounts of the radioisotope 65Zn2+. Of several competing metal ions, tested at 20x the concentration of Zn2+, Cu2+ displaced > 95% of the radioactivity from all three peptides and Ni2+ produced >50% displacement in each case. Some other metal ions tested caused lesser displacement, but Fe2+ and Al3+ were without effect. In a saturation binding assay, a value of 3.2 microM was obtained for the binding of Zn2+ to A beta but our data provided no evidence for a reported higher affinity site (107 nM). The results suggest that the neuropathology associated with the Gly21 mutation is not due to enhanced fibrillogenic or different metal-binding properties of the peptide and that the binding of zinc to amyloid peptides is not a specific phenomenon.

PubMed Disclaimer

Cited by

Amyloid plaques beyond Aβ: a survey of the diverse modulators of amyloid aggregation.
Stewart KL, Radford SE. Stewart KL, et al. Biophys Rev. 2017 Aug;9(4):405-419. doi: 10.1007/s12551-017-0271-9. Epub 2017 Jun 19. Biophys Rev. 2017. PMID: 28631243 Free PMC article. Review.
Metals and amyloid-beta in Alzheimer's disease.
Maynard CJ, Bush AI, Masters CL, Cappai R, Li QX. Maynard CJ, et al. Int J Exp Pathol. 2005 Jun;86(3):147-59. doi: 10.1111/j.0959-9673.2005.00434.x. Int J Exp Pathol. 2005. PMID: 15910549 Free PMC article. Review.
Membrane-targeted strategies for modulating APP and Abeta-mediated toxicity.
Price KA, Crouch PJ, Donnelly PS, Masters CL, White AR, Curtain CC. Price KA, et al. J Cell Mol Med. 2009 Feb;13(2):249-61. doi: 10.1111/j.1582-4934.2008.00642.x. J Cell Mol Med. 2009. PMID: 19278455 Free PMC article. Review.
Metal cations defibrillize the amyloid beta-protein fibrils.
Chauhan VP, Ray I, Chauhan A, Wegiel J, Wisniewski HM. Chauhan VP, et al. Neurochem Res. 1997 Jul;22(7):805-9. doi: 10.1023/a:1022079709085. Neurochem Res. 1997. PMID: 9232632
Chronic exposure to high levels of zinc or copper has little effect on brain metal homeostasis or Abeta accumulation in transgenic APP-C100 mice.
Maynard CJ, Cappai R, Volitakis I, Laughton KM, Masters CL, Bush AI, Li QX. Maynard CJ, et al. Cell Mol Neurobiol. 2009 Jul;29(5):757-67. doi: 10.1007/s10571-009-9401-7. Epub 2009 Apr 21. Cell Mol Neurobiol. 2009. PMID: 19381799 Free PMC article.

Aggregation and metal-binding properties of mutant forms of the amyloid A beta peptide of Alzheimer's disease - PubMed (original) (raw)